albutrepenonacog alfa at a glance
Medicine class
Recombinant, extended-action coagulation factor IX replacement
Licensed use
Preventing and treating bleeding in haemophilia B
Who can use it
Licensed for all age groups
Administration
Slow intravenous injection after the powder is mixed with its supplied solvent
What is albutrepenonacog alfa used for?
Licensed uses in people of any age with haemophilia B caused by congenital factor IX deficiency are:
Prevention of bleeding
Treatment of bleeding
How does albutrepenonacog alfa work?
Factor IX helps activate the clotting pathway that produces fibrin and forms a stable blood clot. Albutrepenonacog alfa replaces deficient factor IX; its albumin component prolongs circulation, then separates when factor IX is activated.
albutrepenonacog alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 3500 units
How to take albutrepenonacog alfa
Treatment is supervised by a haemophilia specialist. After appropriate training, the patient or carer may prepare and inject it intravenously.
Use only the supplied solvent and administration equipment.
Use aseptic technique and gently swirl the vial; do not shake.
The solution should be clear or slightly opalescent and yellow to colourless. Do not use it if cloudy or containing particles.
Inject slowly at a comfortable rate and stop if an immediate reaction occurs.
Record the product name and batch number after each administration.
albutrepenonacog alfa side effects
Common or expected effects
- Headache
- Dizziness
- Rash
- Injection-site reactions
Get urgent medical advice
- Severe hypersensitivity or anaphylaxis, including widespread hives, wheezing, chest tightness, low blood pressure, severe dizziness or breathing difficulty
- Development of factor IX inhibitors, suggested by bleeding that is no longer controlled
- Thrombotic or consumptive-coagulopathy complications, particularly in people with relevant risk factors
albutrepenonacog alfa in pregnancy
Experience during pregnancy is very limited, and reproductive studies have not been conducted. It should be used only when clearly indicated, following assessment by the haemophilia and maternity specialists.
albutrepenonacog alfa while breastfeeding
There is no established experience during breastfeeding. Use should be considered only when clearly indicated after discussion with the haemophilia specialist and maternity or primary-care team.
albutrepenonacog alfa interactions
No interactions between recombinant human factor IX products and other medicines have been reported. The haemophilia team should still be told about all prescribed, non-prescription and complementary products.
Other medicines
No specific interaction is established, but treatment changes should be reviewed by the haemophilia team.
Common questions about albutrepenonacog alfa
Answers are fully visible for fast scanning and source review.
What is albutrepenonacog alfa used for?
It prevents and treats bleeding in people of any age with haemophilia B caused by congenital factor IX deficiency.
Is albutrepenonacog alfa a factor IX treatment?
Yes. It is recombinant factor IX fused to albumin to extend its time in the circulation.
Can children receive albutrepenonacog alfa?
Yes. Its licence covers all age groups, with specialist assessment and monitoring.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.